复方甘草甜素脂质体治疗大鼠非酒精性脂肪性肝炎的疗效观察
|
摘要
目的:观察复方甘草甜素脂质体对大鼠非酒精性脂肪性肝炎(NASH)的治疗作用。
方法:SD雄性大鼠35只随机分为4组,模型组、复方甘草甜素对照组和复方甘草甜素脂质体治疗组各10只,给予高脂饲料喂养,另设5只普通饲料喂养大鼠作为正常组。8周后开始药物干预:模型组生理盐水2.0ml/kg ;对照组复方甘草甜素注射液(SNMC)2.0ml/kg;治疗组复方甘草甜素脂质体注射液2.0ml/kg,以上三组均为隔日腹腔内注射,正常组未予任何药物干预。16周后处死全部实验大鼠。全自动生化分析仪检测血清ALT、AST及GGT水平,参照2006年2月份的NAFLD诊疗指南中脂肪肝分度和炎症分级(NASH-F(0-4)G(0-3))的组织病理学标准进行量化计分。
结果:三组高脂饮食动物的体重、肝指数均比正常组显著增高,三组之间无明显差异。与模型组相比,治疗组血清AST、GGT水平明显降低(P<0.05及P<0.01),肝组织炎症计分显著下降(P<0.01);与对照组比较,治疗组肝组织炎症计分及血清GGT水平均显著降低(P<0.01)。
结论:复方甘草甜素脂质体对高脂饮食诱发的大鼠脂肪性肝炎有一定的防治作用
Objective:To investigate the therapeutic effects of compound glycyrrhizin liposome on the rats with nonalcoholic steatohepatitis
Methods:35 male SD rats were randomly divided into 4 groups:the model group(n=10)、compound glycyrrhizin control group(n=10)and compound glycyrrhizin liposome treated group(n=10) ,the 30 rats all were fed with fat-rich diet,and the normal group(n=5) with normal diet.Drug was given to each group after 8 weeks:the model group were given normal saline (2.0ml/kg) ; the control group were given compound glycyrrhizin injection(2.0ml/kg);the treated group were given compound glycyrrhizin liposome injection(2.0ml/kg) , the three groups all were given by intraperitoneal injection every other day.No any drug was given in normal group.All rats were sacrificed at week 16.The serum levels of ALT、AST and GGT were measured with auto-biochemistry instrument.The hepatic histologic scores on fat-liver and inflammation of NASH were done according to the guidelines of the diagnosis and treatment of NAFLD in February 2006.
Results:The weight and liver index of the three rich-fat diet groups were higher than the normal group,but similar among the three rich-fat diet groups. Compared with model group, the blood-serum levels of AST and GGT both reduced significantly in treated group(P<0.05及P<0.01), the hepatic histologic scores on inflammation of NASH reduced remarkably in treated group(P<0.01);Compared with control group , the hepatic histologic scores on inflammation of NASH and the blood-serum levels of GGT both reduced remarkably in treated group(P<0.01).
Conclusion:Compound glycyrrhizin liposome is effective in treatment of rats with steatohepatitis induced by fat-rich diet .
方法:SD雄性大鼠35只随机分为4组,模型组、复方甘草甜素对照组和复方甘草甜素脂质体治疗组各10只,给予高脂饲料喂养,另设5只普通饲料喂养大鼠作为正常组。8周后开始药物干预:模型组生理盐水2.0ml/kg ;对照组复方甘草甜素注射液(SNMC)2.0ml/kg;治疗组复方甘草甜素脂质体注射液2.0ml/kg,以上三组均为隔日腹腔内注射,正常组未予任何药物干预。16周后处死全部实验大鼠。全自动生化分析仪检测血清ALT、AST及GGT水平,参照2006年2月份的NAFLD诊疗指南中脂肪肝分度和炎症分级(NASH-F(0-4)G(0-3))的组织病理学标准进行量化计分。
结果:三组高脂饮食动物的体重、肝指数均比正常组显著增高,三组之间无明显差异。与模型组相比,治疗组血清AST、GGT水平明显降低(P<0.05及P<0.01),肝组织炎症计分显著下降(P<0.01);与对照组比较,治疗组肝组织炎症计分及血清GGT水平均显著降低(P<0.01)。
结论:复方甘草甜素脂质体对高脂饮食诱发的大鼠脂肪性肝炎有一定的防治作用
Objective:To investigate the therapeutic effects of compound glycyrrhizin liposome on the rats with nonalcoholic steatohepatitis
Methods:35 male SD rats were randomly divided into 4 groups:the model group(n=10)、compound glycyrrhizin control group(n=10)and compound glycyrrhizin liposome treated group(n=10) ,the 30 rats all were fed with fat-rich diet,and the normal group(n=5) with normal diet.Drug was given to each group after 8 weeks:the model group were given normal saline (2.0ml/kg) ; the control group were given compound glycyrrhizin injection(2.0ml/kg);the treated group were given compound glycyrrhizin liposome injection(2.0ml/kg) , the three groups all were given by intraperitoneal injection every other day.No any drug was given in normal group.All rats were sacrificed at week 16.The serum levels of ALT、AST and GGT were measured with auto-biochemistry instrument.The hepatic histologic scores on fat-liver and inflammation of NASH were done according to the guidelines of the diagnosis and treatment of NAFLD in February 2006.
Results:The weight and liver index of the three rich-fat diet groups were higher than the normal group,but similar among the three rich-fat diet groups. Compared with model group, the blood-serum levels of AST and GGT both reduced significantly in treated group(P<0.05及P<0.01), the hepatic histologic scores on inflammation of NASH reduced remarkably in treated group(P<0.01);Compared with control group , the hepatic histologic scores on inflammation of NASH and the blood-serum levels of GGT both reduced remarkably in treated group(P<0.01).
Conclusion:Compound glycyrrhizin liposome is effective in treatment of rats with steatohepatitis induced by fat-rich diet .
引文
1.范建高.非酒精性脂肪肝.2003年上海脂肪肝会议汇编,56-57
2.刘玉兰.非酒精性脂肪肝的流行病学现状,胃肠病学. 2003,8(6):361-363
3. Sheth SG ,Gordon FD ,Chopra S. Nonalco holic steatohepatitis. Ann Intern Med,1997,129(6):137—145
4. Mehta K. Nonalcoholic fatty liver disease:pathogenesis and role of antioxidant Nutrition Rev. 2002 Sep,60(9):289-93
5. GawriehS. Oxidtive stress in nonalcoholic fatty liver disease :pathogenesis and antioxisant theraphies. Investig Med. 2004 Dec;52(8):506-514
6. McCullough AJ. Update on nonalcoholic fatty liver disease. Clin Gastroenterol. 2002 Mar;34(3):255-262
7. Isabelle A. Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis. Clinical Science 2004 10(6):235–237
8. Paul,Ngulo M.D. FATTY LIVER DISEASE N Engl J Med, Vol. 346, No. 16 April 18, 2002 1221-1231
9.窦爱霞,陆伦根.胰岛素抵抗和非酒精性脂肪性肝病研究进展.世界华人消化杂志. 2006,14(12): 1197-1202
10.于洪波非酒精性脂肪肝炎发病机制研究现状.临床消化病杂志.2005,17(5) 252-253
11. Juergen Siebler, Peter R Galle. Treatment of nonalcoholic fatty liver disease .World J Gastroenterol 2006 April 14; 12(14): 2161-2167
12. Tokar JL. Therapeutic Options in Nonalcoholic Fatty Liver Disease.Curr Treat Options Gastroenterol. 2002 Dec;5(6):425-436
13. Carl M. Oneta. Non-alcoholic fatty liver disease: treatmentoptions based on pathogenic considerations, SWISS MED WKLY 2002;132:493–505
14. Sh. Ravanshad1, B. Therapeutic Effects of Restricted Diet in Obest Patients with Non-alcoholic fatty liver disease.J Med Sci 2005 ,21(4) 472-475
15.方继伟,范建高.非酒精性脂肪性肝病的治疗现状.中华肝脏病杂志.2003, 11(2期):120-122。
16. Bugianesi E .A randomized controlled trial of metformin versus vitanmin E or prescriptive diet in nonalcoholic fatty liver disease Am J Gastroenterol.2005 May;100(5):1082-1090
17. Nair S. Metformin in the treatment of nonalcoholic steatohepatitis:a pilot open label trial Aliment Pharmacol Ther. 2004 Jul 1;20(1):23-28
18. Abdelmalek MF.Betaine a promising new agent for patient with nonalcoholic steatohepatitis result of Nonalcoholic Fatty Liver Disease: a pilot study. Am J Gastroenterol. 2001 Sep;96(9):2711-2717
19. Ersoz G .Management of fatty liver disedse with vitamin E and C compared to ursodeoxycholic acid treatment.Turk J Gastroenterol. 2005 Sep;16(3):124-128
20. Sanyal AJ. A pilot study of vitanminE versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-1115
21. Madan K. Vitamin E-based theraphy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian J Gastroenterol. 2005 Nov-Dec;24(6):251-255
22.丁晓东,范建高.二甲双胍干预大鼠非酒精性脂肪性肝炎疗效观察.肝脏,2005,10(2):79-81
23.张海,韩志启.凯西莱治疗非酒精性脂肪肝的疗效观察. Chinese Journal of Microecology,2004,16(5) :306
24.范建高钟岚.熊去氧胆酸对高脂饮食大鼠脂肪性肝炎形成的影响. Chinese Hepatology,June 2001,6(2):86-87
25. Veldt BJ, Hansen BE.Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol. 2006 Sep,41(9):1087-94
26. Orlent H, Hansen BE. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phaseⅡtrial. J Hepatol. 2006 Oct;45(4):539-46
27. Yao WH, Zhao W, Effect of compound glycyrrhizin on peripheral T-lymphocyte subset in AIDS Patients Zhonghua Nan Ke Xue. 2006 Jul;12(7):598-601
28. Hoever G, Baltina L, Antiviral activity of glycyrrhizic acid derivatives again SARS-coronavirus. J Med Chem. 2005 Feb 24;48(4):1256-9
29. Fujioka T, Kondou T, Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C:a pilot study. Hepatol Res. 2003 May;26(1):10-14.
30. Van Rossum TG, Vulto AG, Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol. 2001 Aug;96(8):2432-7.
31.王志凌,张连峰,成军.甘草甜素诱导的大鼠肝星状细胞差异表达基因检测郑州大学学报(医学版) 2006, 41(3):512-513
32.王志凌,成军等.甘草甜素抑制肝星状细胞增殖作用的研究.肝脏.2005,lO(3): 225-226
33.马中春.甘草甜素对四氯化碳诱发大鼠肝脏损伤的作用及其机制.毒理学杂志.2005,19(3)增刊:250-251
34.陆伦根,曾民德.甘草酸二胺脂质配位体对大鼠酒精性脂肪肝的治疗作用.中国天然药物, 2004,2(6): 372-375
35.刘协,顾呈华.甘草甜素脂质体对小鼠急性酒精性肝损伤的保护作用.中国临床康复,2004,8(36): 8260-8261
36.张建,唐红敏.甘草甜素多相脂质体对非酒精性脂肪肝肝功能的影响.肝脏.2003,8(3): 30-31
37.马金刚,李迎雁.脂质体研究进展.中华现代医学与临床.2005, 3(7):41-43
38.于波涛,张志荣等.脂质体稳定性的研究进展.西南国防医药.2005,15(6):686-688
39.李祖惠,杨辉.脂质体药物研究进展.中国药业.2005,14(10):75-76
1.范建高,丁晓东.非酒精性脂肪性肝病的治疗.脂肪性肝病诊疗进展,中华医学电子音像出版社:48-52。
2.Mendez-Sanchez N,Gonzalez V. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease.A double-blind.placebo-controlled trial.Ann Hepatol.2004 3(3):108-112
3.Hickman IJ,Jonsson JR. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase,fasting insulin,and quality of life. Gut 2004 Mar;53(3):413-419。
4.范建高,徐正捷.美国非酒精性脂肪性肝病的诊断与治疗共识.Chinese Hepatology,2003 Mar;18(1):58。
5.中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南.中华肝脏病杂志,2006,14(3) :161-163.
6.Chavez-Tapia NC.Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.Am J Med Sci. 2007 Nov;334(5):327-30.
7.丁晓东、范建高等.二甲双胍干预大鼠非酒精性脂肪性肝炎疗效观察.肝脏.2005,10(2):79-81。
8.BugianesiE,Gentilcore E. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol.2005 May;100(5):1082-1090。
9.Nair S , Diehl AM. Metformin in treatment of non-alcoholicsteatohepatitis:a pilot open label trial. Aliment Pharmacol Ther. 2004 Jul;20(1):23-28。
10. Duseja A, Das A. Metformin is effective in acieving biochemical response in patients with nonalcoholic fatty liver disease not responding interventions. Ann Hepatol.2007 Oct-Dec;6(4):222-6.
11.陈志平.二甲双胍治疗非酒精性脂肪肝病的研究进展.现代医药卫生.2008,24(3):360-362。
12.窦艳玲赵洪川.二甲双胍联合生活方式干预对非酒精性脂肪肝的治疗作用.中国实用内科杂志.2007,27(7):523-525。
13.韦小玲,王艳荣等.罗格列酮治疗非酒精性脂肪肝的实验研究.中国糖尿病杂志. 2006,14(4):277-280。
14. Sanyal AJ, Mofrad PS . A polot study of vitaminE versus and vitaminE and pioglitazone for the treantment of nonacoholic steatohepatitis.Clin Gastroenterol Hepatol.2004 Dec;2(12):1107-1115
15. Promart K. A pilot study of pioglitazone treatment for nonacoholic steatohepatitis.Hepatology.2004;39(1):188-196
16.向阳,叶家润.吡格列酮对非酒精性脂肪肝的疗效观察.临床肝胆病杂志.2007,23(6):434-435。
17.郅敏,陈旻湖.罗格列酮对高脂饮食诱导非酒精性脂肪肝大鼠胰岛素抵抗及脂联素的影响.世界华人消化杂志.2007,15(27):2869-2874。
18. Mehta K, Van Thiel DH. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev. 2002 Sep;60(9):289-93.
19. Harrison SA, Ward JA .The role of vitamin E and C therapy in NASH. Am J Gastroenterol. 2003 Nov;98(11):2348-2350.
20. Ersoz.G,Gunsar F.Management of fatty liver disease with vitaminE and vitamin C compared to ursodeoxycholic acid treatment.Turk J Gastroenterol.2005 sep;16(3):124-128。
21. Harrison SA,Torderson S. Vitamin E and vitamin C treatment improve fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003 Nov;98(11):2485-2490。
22. Madan K, Batra Y. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease.Indian J Gastroenterol.2005 24(6):251-255.
23. Oliveira CP, Gayotto LC.Vitamin C and vitamin E in prevention of Nonalcoholic Fatty Liver Disease (NAFLD) in choline deficient diet fed rats. Nutr J. 2003 Oct 2:9.
24.金怒云、余小虎等.还原型谷胱甘肽治疗非酒精性脂肪肝40例.中国药业.2005,14(12):79-80。
25.杨朝霞代东伶.还原型谷胱甘肽对实验性大鼠非酒精性脂肪肝的疗效观察及其分子机制探讨.重庆医科大学学报,2005,30(6):803-807。
26.张海、韩志启.凯西莱治疗非酒精性脂肪肝的疗效观察.Chinese Microecology. 2004,16(5):306。
27.吴春晓,郑智雄等.凯西莱联合甘利欣治疗非酒精性脂肪肝.黑龙江医学.2005,29(12):891-893。
28.周骥林志宇.凯西莱联合脂必妥治疗非酒精性脂肪性肝炎.四川医学.2005,26(11):1258。
29. Santos VN,Lanzoni VP. A randomized double-blind study of the short-time trement of obese patients with nonalcoholic fatty liver diaease with ursodeoxycholic acid. Braz J Med Biol Res.2003 Jun;36(6):723-729。
30. Lindor KD,Kowdely KV. Ursodeoxycholic acid for treatment ofnonalcoholic steatohepatitis:result of a randomized trial. Hepatology, 2004 Mar;39(3):602-603。
31.范建高,钟岚等.熊去氧胆酸对高脂饮食大鼠脂肪性肝炎形成的影响.Chinese Hepatology. 2001,6(2):82-83。
32.申泽.易善复治疗非酒精性脂肪肝100例疗效观察.中华现代临床医学杂志.2007,5(8):693-694
33.江庆澜,徐邦牢等.多烯磷脂酰胆碱对非酒精性脂肪肝大鼠的干预效果.广州医学院学报.2005,33(4):4-6。
34.姜兆金雷明君.多烯磷脂酰胆碱治疗非酒精性脂肪肝疗效观察.传染病信息.2007,20(3):176-177。
35.文毅曾连招.易善复、水飞蓟宾治疗非酒精性脂肪肝临床疗效观察.临床和实验医学杂志.2007,6(6):94-95。
36.徐小虎,朱金水等.水飞蓟素联合二甲双胍治疗肥胖型非酒精性脂肪肝疗效分析.胃肠病学和肝病学杂志.2006,15(5):485—487。
37.邢凌翔贺永文.水飞蓟素对大鼠非酒精性脂肪性肝炎的防治作用及机制.胃肠病学和肝病学杂志,2007 ,16(1):60-62。
38. Abdelmalek MF,Angulo P.Betaine ,a promising new agent for patinents with nonalcohilic steatohepatitis results of a pilot study. Am J Gastroenterol. 2001 Sep;96(9):2711-2717
39.张建,唐红敏等.甘草甜素多相脂质体对非酒精性脂肪肝肝功能的影响. Chinese Hepatology. 2003,8(3):30-32。
40.宋波,温伟波.甘利欣配合三七粉治疗非酒精性脂肪肝42例疗效观察.云南中医中药杂志.2006,27(2):6-7。
2.刘玉兰.非酒精性脂肪肝的流行病学现状,胃肠病学. 2003,8(6):361-363
3. Sheth SG ,Gordon FD ,Chopra S. Nonalco holic steatohepatitis. Ann Intern Med,1997,129(6):137—145
4. Mehta K. Nonalcoholic fatty liver disease:pathogenesis and role of antioxidant Nutrition Rev. 2002 Sep,60(9):289-93
5. GawriehS. Oxidtive stress in nonalcoholic fatty liver disease :pathogenesis and antioxisant theraphies. Investig Med. 2004 Dec;52(8):506-514
6. McCullough AJ. Update on nonalcoholic fatty liver disease. Clin Gastroenterol. 2002 Mar;34(3):255-262
7. Isabelle A. Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis. Clinical Science 2004 10(6):235–237
8. Paul,Ngulo M.D. FATTY LIVER DISEASE N Engl J Med, Vol. 346, No. 16 April 18, 2002 1221-1231
9.窦爱霞,陆伦根.胰岛素抵抗和非酒精性脂肪性肝病研究进展.世界华人消化杂志. 2006,14(12): 1197-1202
10.于洪波非酒精性脂肪肝炎发病机制研究现状.临床消化病杂志.2005,17(5) 252-253
11. Juergen Siebler, Peter R Galle. Treatment of nonalcoholic fatty liver disease .World J Gastroenterol 2006 April 14; 12(14): 2161-2167
12. Tokar JL. Therapeutic Options in Nonalcoholic Fatty Liver Disease.Curr Treat Options Gastroenterol. 2002 Dec;5(6):425-436
13. Carl M. Oneta. Non-alcoholic fatty liver disease: treatmentoptions based on pathogenic considerations, SWISS MED WKLY 2002;132:493–505
14. Sh. Ravanshad1, B. Therapeutic Effects of Restricted Diet in Obest Patients with Non-alcoholic fatty liver disease.J Med Sci 2005 ,21(4) 472-475
15.方继伟,范建高.非酒精性脂肪性肝病的治疗现状.中华肝脏病杂志.2003, 11(2期):120-122。
16. Bugianesi E .A randomized controlled trial of metformin versus vitanmin E or prescriptive diet in nonalcoholic fatty liver disease Am J Gastroenterol.2005 May;100(5):1082-1090
17. Nair S. Metformin in the treatment of nonalcoholic steatohepatitis:a pilot open label trial Aliment Pharmacol Ther. 2004 Jul 1;20(1):23-28
18. Abdelmalek MF.Betaine a promising new agent for patient with nonalcoholic steatohepatitis result of Nonalcoholic Fatty Liver Disease: a pilot study. Am J Gastroenterol. 2001 Sep;96(9):2711-2717
19. Ersoz G .Management of fatty liver disedse with vitamin E and C compared to ursodeoxycholic acid treatment.Turk J Gastroenterol. 2005 Sep;16(3):124-128
20. Sanyal AJ. A pilot study of vitanminE versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-1115
21. Madan K. Vitamin E-based theraphy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian J Gastroenterol. 2005 Nov-Dec;24(6):251-255
22.丁晓东,范建高.二甲双胍干预大鼠非酒精性脂肪性肝炎疗效观察.肝脏,2005,10(2):79-81
23.张海,韩志启.凯西莱治疗非酒精性脂肪肝的疗效观察. Chinese Journal of Microecology,2004,16(5) :306
24.范建高钟岚.熊去氧胆酸对高脂饮食大鼠脂肪性肝炎形成的影响. Chinese Hepatology,June 2001,6(2):86-87
25. Veldt BJ, Hansen BE.Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol. 2006 Sep,41(9):1087-94
26. Orlent H, Hansen BE. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phaseⅡtrial. J Hepatol. 2006 Oct;45(4):539-46
27. Yao WH, Zhao W, Effect of compound glycyrrhizin on peripheral T-lymphocyte subset in AIDS Patients Zhonghua Nan Ke Xue. 2006 Jul;12(7):598-601
28. Hoever G, Baltina L, Antiviral activity of glycyrrhizic acid derivatives again SARS-coronavirus. J Med Chem. 2005 Feb 24;48(4):1256-9
29. Fujioka T, Kondou T, Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C:a pilot study. Hepatol Res. 2003 May;26(1):10-14.
30. Van Rossum TG, Vulto AG, Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol. 2001 Aug;96(8):2432-7.
31.王志凌,张连峰,成军.甘草甜素诱导的大鼠肝星状细胞差异表达基因检测郑州大学学报(医学版) 2006, 41(3):512-513
32.王志凌,成军等.甘草甜素抑制肝星状细胞增殖作用的研究.肝脏.2005,lO(3): 225-226
33.马中春.甘草甜素对四氯化碳诱发大鼠肝脏损伤的作用及其机制.毒理学杂志.2005,19(3)增刊:250-251
34.陆伦根,曾民德.甘草酸二胺脂质配位体对大鼠酒精性脂肪肝的治疗作用.中国天然药物, 2004,2(6): 372-375
35.刘协,顾呈华.甘草甜素脂质体对小鼠急性酒精性肝损伤的保护作用.中国临床康复,2004,8(36): 8260-8261
36.张建,唐红敏.甘草甜素多相脂质体对非酒精性脂肪肝肝功能的影响.肝脏.2003,8(3): 30-31
37.马金刚,李迎雁.脂质体研究进展.中华现代医学与临床.2005, 3(7):41-43
38.于波涛,张志荣等.脂质体稳定性的研究进展.西南国防医药.2005,15(6):686-688
39.李祖惠,杨辉.脂质体药物研究进展.中国药业.2005,14(10):75-76
1.范建高,丁晓东.非酒精性脂肪性肝病的治疗.脂肪性肝病诊疗进展,中华医学电子音像出版社:48-52。
2.Mendez-Sanchez N,Gonzalez V. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease.A double-blind.placebo-controlled trial.Ann Hepatol.2004 3(3):108-112
3.Hickman IJ,Jonsson JR. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase,fasting insulin,and quality of life. Gut 2004 Mar;53(3):413-419。
4.范建高,徐正捷.美国非酒精性脂肪性肝病的诊断与治疗共识.Chinese Hepatology,2003 Mar;18(1):58。
5.中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南.中华肝脏病杂志,2006,14(3) :161-163.
6.Chavez-Tapia NC.Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.Am J Med Sci. 2007 Nov;334(5):327-30.
7.丁晓东、范建高等.二甲双胍干预大鼠非酒精性脂肪性肝炎疗效观察.肝脏.2005,10(2):79-81。
8.BugianesiE,Gentilcore E. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol.2005 May;100(5):1082-1090。
9.Nair S , Diehl AM. Metformin in treatment of non-alcoholicsteatohepatitis:a pilot open label trial. Aliment Pharmacol Ther. 2004 Jul;20(1):23-28。
10. Duseja A, Das A. Metformin is effective in acieving biochemical response in patients with nonalcoholic fatty liver disease not responding interventions. Ann Hepatol.2007 Oct-Dec;6(4):222-6.
11.陈志平.二甲双胍治疗非酒精性脂肪肝病的研究进展.现代医药卫生.2008,24(3):360-362。
12.窦艳玲赵洪川.二甲双胍联合生活方式干预对非酒精性脂肪肝的治疗作用.中国实用内科杂志.2007,27(7):523-525。
13.韦小玲,王艳荣等.罗格列酮治疗非酒精性脂肪肝的实验研究.中国糖尿病杂志. 2006,14(4):277-280。
14. Sanyal AJ, Mofrad PS . A polot study of vitaminE versus and vitaminE and pioglitazone for the treantment of nonacoholic steatohepatitis.Clin Gastroenterol Hepatol.2004 Dec;2(12):1107-1115
15. Promart K. A pilot study of pioglitazone treatment for nonacoholic steatohepatitis.Hepatology.2004;39(1):188-196
16.向阳,叶家润.吡格列酮对非酒精性脂肪肝的疗效观察.临床肝胆病杂志.2007,23(6):434-435。
17.郅敏,陈旻湖.罗格列酮对高脂饮食诱导非酒精性脂肪肝大鼠胰岛素抵抗及脂联素的影响.世界华人消化杂志.2007,15(27):2869-2874。
18. Mehta K, Van Thiel DH. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev. 2002 Sep;60(9):289-93.
19. Harrison SA, Ward JA .The role of vitamin E and C therapy in NASH. Am J Gastroenterol. 2003 Nov;98(11):2348-2350.
20. Ersoz.G,Gunsar F.Management of fatty liver disease with vitaminE and vitamin C compared to ursodeoxycholic acid treatment.Turk J Gastroenterol.2005 sep;16(3):124-128。
21. Harrison SA,Torderson S. Vitamin E and vitamin C treatment improve fibrosis in patients with nonalcoholic steatohepatitis.Am J Gastroenterol,2003 Nov;98(11):2485-2490。
22. Madan K, Batra Y. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease.Indian J Gastroenterol.2005 24(6):251-255.
23. Oliveira CP, Gayotto LC.Vitamin C and vitamin E in prevention of Nonalcoholic Fatty Liver Disease (NAFLD) in choline deficient diet fed rats. Nutr J. 2003 Oct 2:9.
24.金怒云、余小虎等.还原型谷胱甘肽治疗非酒精性脂肪肝40例.中国药业.2005,14(12):79-80。
25.杨朝霞代东伶.还原型谷胱甘肽对实验性大鼠非酒精性脂肪肝的疗效观察及其分子机制探讨.重庆医科大学学报,2005,30(6):803-807。
26.张海、韩志启.凯西莱治疗非酒精性脂肪肝的疗效观察.Chinese Microecology. 2004,16(5):306。
27.吴春晓,郑智雄等.凯西莱联合甘利欣治疗非酒精性脂肪肝.黑龙江医学.2005,29(12):891-893。
28.周骥林志宇.凯西莱联合脂必妥治疗非酒精性脂肪性肝炎.四川医学.2005,26(11):1258。
29. Santos VN,Lanzoni VP. A randomized double-blind study of the short-time trement of obese patients with nonalcoholic fatty liver diaease with ursodeoxycholic acid. Braz J Med Biol Res.2003 Jun;36(6):723-729。
30. Lindor KD,Kowdely KV. Ursodeoxycholic acid for treatment ofnonalcoholic steatohepatitis:result of a randomized trial. Hepatology, 2004 Mar;39(3):602-603。
31.范建高,钟岚等.熊去氧胆酸对高脂饮食大鼠脂肪性肝炎形成的影响.Chinese Hepatology. 2001,6(2):82-83。
32.申泽.易善复治疗非酒精性脂肪肝100例疗效观察.中华现代临床医学杂志.2007,5(8):693-694
33.江庆澜,徐邦牢等.多烯磷脂酰胆碱对非酒精性脂肪肝大鼠的干预效果.广州医学院学报.2005,33(4):4-6。
34.姜兆金雷明君.多烯磷脂酰胆碱治疗非酒精性脂肪肝疗效观察.传染病信息.2007,20(3):176-177。
35.文毅曾连招.易善复、水飞蓟宾治疗非酒精性脂肪肝临床疗效观察.临床和实验医学杂志.2007,6(6):94-95。
36.徐小虎,朱金水等.水飞蓟素联合二甲双胍治疗肥胖型非酒精性脂肪肝疗效分析.胃肠病学和肝病学杂志.2006,15(5):485—487。
37.邢凌翔贺永文.水飞蓟素对大鼠非酒精性脂肪性肝炎的防治作用及机制.胃肠病学和肝病学杂志,2007 ,16(1):60-62。
38. Abdelmalek MF,Angulo P.Betaine ,a promising new agent for patinents with nonalcohilic steatohepatitis results of a pilot study. Am J Gastroenterol. 2001 Sep;96(9):2711-2717
39.张建,唐红敏等.甘草甜素多相脂质体对非酒精性脂肪肝肝功能的影响. Chinese Hepatology. 2003,8(3):30-32。
40.宋波,温伟波.甘利欣配合三七粉治疗非酒精性脂肪肝42例疗效观察.云南中医中药杂志.2006,27(2):6-7。